Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for low anterior resection syndrome after rectal cancer treatment
ISRCTN48772765Phase 2Terminated
- Sponsor
- Nottingham University Hospitals
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in low anterior resection syndrome (LARS) comparing Ondansetron with Placebo (2 arms). Primary endpoint: Proportion of days with no or mild urgency. Started Feb 2020; status: terminated.
02
Drugs
ondansetron
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on ISRCTN48772765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48772765.